Orchestra BioMed Holdings (OBIO) Restructuring Costs (2021)
Orchestra BioMed Holdings' (OBIO) quarterly Restructuring Costs came in at $30000.0 in Q1 2021.
Orchestra BioMed Holdings (OBIO) Restructuring Costs (2021) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 1 years of Restructuring Costs data on file, last reported at $30000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Orchestra BioMed Holdings | 235.83 Mn | 141.43 Mn | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 30,000.00 |